Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DRL_AB · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DRL_AB 125 mg via AI | EXPERIMENTAL | Participants will receive a single subcutaneous (SC) dose of DRL\_AB, 125 milligrams (mg) in an AI on Day 1 of the treatment period of 70 days. |
| DRL_AB 125 mg via PFS | ACTIVE_COMPARATOR | Participants will receive a single SC dose of DRL\_AB, 125 mg in a PFS on Day 1 of the treatment period of 70 days. |
| Name | Type | Description |
|---|---|---|
| DRL_AB | BIOLOGICAL | DRL\_AB administered as a SC injection. |
Inclusion Criteria: 1. Healthy male volunteers aged 18 to 50 years (both inclusive) at the time of signing informed consent form. 2. Ability and amenability to provide written informed consent to participate in the study and adhere to study requirements. 3. Body mass index in the range 18.5-30.0 ki...
DRL_AB is an investigational monoclonal antibody being developed by Dr. Reddy's Laboratories Ltd. It is in Phase 1 clinical development, with one active trial in healthy male volunteers. No approved indication has been announced, and the therapeutic indication for the program has not been disclosed.
DRL_AB targets CD80 and CD86, two costimulatory molecules involved in T-cell activation. By binding these targets, the monoclonal antibody is designed to modulate CD80/CD86-mediated immune signaling. This target profile places DRL_AB among antibody therapeutics directed at costimulation pathways rather than at cytokines or cell-surface tumor antigens.
DRL_AB is being developed by Dr. Reddy's Laboratories Ltd, an Indian pharmaceutical company whose shares trade under the ticker RDY. Dr. Reddy's is the sponsor of the DRL_AB clinical program, which currently consists of a single Phase 1 study conducted in New Zealand.
DRL_AB is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved for any indication. The program's only registered trial is a Phase 1 pharmacokinetic study, and no later-phase trials have been registered for this asset.
DRL_AB is being studied in NCT07744828, titled A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants. The Phase 1 trial is not yet recruiting, plans to enroll 160 healthy male volunteers aged 18 years and older, is randomized and active-controlled, and is being run in New Zealand.